Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-prenylnaringenin is a prenylflavonoid phytoestrogen found primarily in hops (Humulus lupulus) and beer[4][15]. It is among the most estrogenic phytoestrogens known, acting as a potent agonist of the estrogen receptors, especially ERα, and to a lesser extent ERβ[1][4][10][13]. Its activity is 50–1500 times greater than genistein or daidzein but is markedly less potent than estradiol[1][4]. 8-prenylnaringenin exhibits both estrogenic and antigonadotropic activities, suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in humans[4][7]. It has demonstrated effects similar to estradiol, including preserving bone density, reducing hot flashes, inducing prolactin secretion, and increasing other estrogenic responses[4]. Beyond endocrine effects, it displays anticancer properties in vitro, such as inhibition of proliferation and induction of apoptosis in various cancer cell lines, likely associated with inhibition of voltage-gated Kv1.3 potassium channels[1][4]. It can also enhance GABA_A receptor activity[4]. The compound is being studied as a possible alternative to hormone replacement therapy (HRT) and for management of menopause-related symptoms[1][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-prenylnaringenin.